Accès membres

Bienvenue sur le site du Groupe d’étude des Tumeurs Endocrines

Le groupe d'étude des tumeurs endocrines est une société savante créée en 2002 réunissant les différentes spécialités impliquées dans la prise en charge des tumeurs neuro-endocrines (TNE) : anatomopathologistes, biologistes, chirurgiens, endocrinologues, gastroentérologues, généticiens, médecins nucléaires, oncologues et radiologues.

CLARINET Forte

Type d'étude Promoteur Etat actuel de l'étude
Phase II IPSEN En cours de recrutement

 

Efficacy and safety of Somatuline Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable gastro-entero-pancreatic neuroendocrine tumours having progressed radiologically while previously treated with Somatuline Autogel® 120 mg administered every 28 days.
Open label, single arm, non-comparative, multicentre study.

Code de l’étude

CLARINET Forte

Promoteur/ sponsor

IPSEN

Tumeur éligible

TNE gastroenteropancréatique

Type d’étude

Interventionnelle :  Somatuline Autogel® 120 mg administered every 14 days

Phase

 Open label, single arm, non-comparative, multicentre study

Nombre de patients à inclure

100 patients (50 midgut, 50 pancréas)

Investigateur(s) principal

Pr. Ruszniewski  (Clichy)

Centres Français

Lyon, Marseille, Clichy, Villejuif

Objectifs

Objectif principal : Progression Free Survival

Objectifs secondaires :
• To evaluate the clinical and biological safety profile.
• To evaluate time to progression.
• To evaluate PFS and survival rates every 12 weeks.
• To evaluate overall survival at 1 and 3 years.
• To evaluate the objective response rate as per RECIST 1.0.
• To detect predictive factors of PFS.
• To evaluate the effect on symptoms (diarrhoea, flushing) in symptomatic patients.
• To evaluate the changes in tumour biomarkers: chromogranin A, other tumour peptide markers with elevated level at baseline
* To evaluate the appearance of lanreotide antibodies.
• To evaluate the pharmacokinetic profile in relation to pharmacodynamics (PFS, tumour response or chromogranin A)

Critères d’inclusion

-    Histopathologically confirmed, grade 1 or 2, metastatic or locally advanced, unresectable pNET (pNET cohort) or midgut NET (midgut cohort) with or without hormone related syndromes, with a proliferation index (Ki67) ?20%.
-    Positive somatostatin receptors type 2
-    Progression as assessed by an independent central reviewer according to RECIST v1.0 while receiving first line treatment with lanreotide Autogel® at a standard dose of 120 mg every 28 days for at least 24 weeks

Critères d’exclusion  

•    Grade 3 or rapidly progressive (within 12 weeks) NET
•    Any NET other than pancreatic and midgut
•    Previous treatment with any antitumour agent for NET other than lanreotide Autogel® 120 mg every 28 days
•    Gallbladder lithiasis at Screening echography or history of cholelithiasis with no cholecystectomy since then